A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world study

Azoulai, Marion; Lévy-Heidmann, Tiphaine; Morisseau, Valentin; Wilczynski, Ophélie; Le, Hoa H.; Jamieson, Carol; Charvet, Leigh; Krupp, Lauren; Lair, Lindsey

doi:10.1016/j.msard.2022.103637

Cited by 2 publications

(3 citation statements)

References 38 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 One study has evaluated the effect of RTX on MS-related fatigue with negative results. 15 Previous comparative studies of fatigue have grouped DMTs into efficacy categories or by method of administration, 21 , 22 making comparisons to our results difficult. In a recent study, Azoulai et al evaluated fatigue in 300 patients with MS treated with high-efficacy drugs (NTZ, RTX, and ocrelizumab) in comparison with other DMTs.…”

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 94%

“…In a recent study, Azoulai et al evaluated fatigue in 300 patients with MS treated with high-efficacy drugs (NTZ, RTX, and ocrelizumab) in comparison with other DMTs. 21 No significant differences between groups were seen suggesting that differences in fatigue between treatment options are likely to be small and in need of large study cohorts for detectability.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Hellgren,

Strandberg,

Källén

et al. 2024

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Background Fatigue is the most debilitating symptom in patients with multiple sclerosis (MS). Natalizumab and rituximab are the most used MS disease modifying therapies in Sweden, but comparative data on the effect on fatigue is sparse. Objective Primary objective was to compare fatigue levels between patients on natalizumab and rituximab. As secondary objective, we assessed processing speed, an attention domain quality, between treatment groups. Method In this Swedish multicentre cross-sectional study, patients with relapsing-remitting MS and >24 months treatment duration were identified in the Swedish MS-registry. Fatigue was assessed using the Fatigue Scale for Motor and Cognitive functions (FSMC) and processing speed using Symbol Digit Modalities Test (SDMT). Results 128 patients were enrolled (natalizumab: 56, rituximab: 72). No significant differences in FSMC were found when adjusting for potential confounders (p = 0.936), with age having the biggest impact, correlating with increased fatigue. Individuals on natalizumab performed significantly better on SDMT at cross-section (natalizumab 64.7, rituximab 56.2; p = 0.003), with an improvement from treatment initiation, compared to rituximab (change: natalizumab 8.9, rituximab −1.0; p = 0.002). Conclusion We found no difference in fatigue levels between natalizumab and rituximab cohorts. Patients treated with natalizumab showed significantly better results on SDMT than patients on rituximab.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Hellgren,

Strandberg,

Källén

et al. 2024

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

show abstract

Sleep Disorders and Sleep Disturbances in Persons with Multiple Sclerosis: A Population-Based Matched Case-Control Study in Denmark

Framke,

Jennum,

Thygesen

et al. 2024

Neuroepidemiology

View full text Add to dashboard Cite

Introduction: Adverse sleep is common in multiple sclerosis (MS). Population-based studies including adequate control groups are lacking. We hypothesized that the prevalence of sleep disorders and other sleep disturbances would be higher in persons with MS than in controls. Methods: We conducted a population-based study linking individual-level data from the Danish MS Registry (n = 21,943 persons with MS) and the Danish Population Registry (n = 109,715 matched controls) with information on sleep disorders from the Danish National Patient Registry and other sleep disturbances assessed by dispensed prescription drugs from the Danish National Prescription Registry. Results: Prevalence of diagnosed sleep disorders in terms of central hypersomnia (0.15% vs. 0.06%), sleep disturbances (1.05% vs. 0.70%), and sleep movements (0.22% vs. 0.13%) and other sleep disturbances identified by dispensed central acting (10.73% vs. 1.10%) and hypnotic use (30.65% vs. 20.13%) medication was statistically significantly higher among persons with MS when compared to controls. We found no statistically significant difference in the prevalence of sleep apnea and parasomnia between groups. Stratified by sex and age at MS diagnosis, results for differences between persons with MS and controls were similar. Conclusion: In this registry-based study, we found that the prevalence of several diagnosed sleep disorders was higher in persons with MS than in controls, that is, those reflecting insomnia and daytime symptoms including hypersomnia. Other sleep disturbances identified by dispensed prescription medication were markedly higher in persons with MS than in controls.

show abstract

A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world study

Cited by 2 publications

References 38 publications

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Sleep Disorders and Sleep Disturbances in Persons with Multiple Sclerosis: A Population-Based Matched Case-Control Study in Denmark

Contact Info

Product

Resources

About